You just read:

SUNFISH Pivotal Results for Risdiplam (RG7916) Demonstrate Medically Meaningful Benefit in Broadest Age Group of Patients Studied with Type 2 and 3 Spinal Muscular Atrophy

News provided by

PTC Therapeutics, Inc.

Feb 06, 2020, 05:00 ET